TG Therapeutics TGTX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's accounts payable?
- TG Therapeutics (TGTX) reported accounts payable of $148.85M in Q1 2026.
- How has TG Therapeutics's accounts payable changed year-over-year?
- TG Therapeutics's accounts payable increased by 11.1% year-over-year, from $133.93M to $148.85M.
- What is the long-term trend for TG Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), TG Therapeutics's accounts payable has grown at a 23.8% compound annual growth rate (CAGR), from $37.01M to $107.51M.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods or services received.
- How do you interpret accounts payable?
- An increase can signal improved cash management through extended payment terms, whereas a decrease may indicate faster payments or reduced purchasing activity.
- How does accounts payable compare across companies?
- Biotech companies typically maintain accounts payable levels consistent with their R&D and commercialization spending cycles.